Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dual-Task breathing training aims to boost brain power in heart failure

NCT ID NCT07581587

Symptom relief Sponsor: Istanbul University - Cerrahpasa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests whether combining breathing exercises with cognitive tasks (like memory games) can improve thinking and daily function in adults with heart failure. 54 participants will be randomly assigned to dual-task breathing training, standard breathing training, or a control group. The training lasts 8 weeks, mostly done at home via video calls. Researchers will measure changes in memory, attention, reaction time, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inspiratory muscle training (breathing exercises) with or without simultaneous cognitive tasks
What this could lead to
If it works, this could point toward a simple, home-based way to improve memory, attention, and quality of life for people with heart failure.
What could go wrong
This is a small, early-stage trial with only 54 participants, so results may not apply to everyone. The improvements, if any, might be modest or not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 40 years * Diagnosed with HF with reduced ejection fraction (HFrEF) according to the 2023 ESC HF Guidelines * Classified as NYHA functional class I-III * Clinically stable for at least 3 months and receiving stable pharmacological treatment * Able to read and understand Turkish * MoCA score ≥ 21 * Willingness to participate and provide written informed consent Exclusion Criteria: * Diagnosis of any neurological or neurodegenerative disease (e.g., Parkinson's disease, stroke, dementia, Alzheimer's disease) * Diagnosis of pulmonary disease (e.g., chronic obstructive pulmonary disease, obstructive sleep apnea) * Myocardial infarction within the last 6 months * Uncontrolled hypertension and/or diabetes mellitus * Severe valvular heart disease and/or uncontrolled arrhythmias * Orthopedic, visual, or hearing impairments that may prevent independent test completion * Inability to comply with study procedures or follow instructions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul University-Cerrahpaşa, Cardiology Institute

    RECRUITING

    Istanbul, Fatih, 34098, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.